Keywords
How to Cite
Abstract
Objective: Identify the prostate cancer detection rate in patients in whom underwent a saturation prostate biopsy as a rebiopsy from January 2005 to February 2015 at San Ignacio Hospital. Materials and methods: In San Ignacio hospital were performed from January 2005 to February 2015, 114 saturation biopsies. The investigators made a univariate analysis of the variables. The association between the variable was evaluated based on the T-test and Wilcoxon test. P < 0.05 was considered statistically significant. Finally, a regression model was performed to predict significant variables for prostate cancer. Results: The cancer detection rate using saturation prostate biopsy was 16.7% of which 84% were categorized as significant. A mean of 19 cores were obtained. There were statistically significant differences between patients with prostate cancer and healthy patients in the number of previous biopsies, number of samples, prostate volume and PSA density. Conclusion: Saturation prostate biopsy in our study has a prostate cancer detection rate of 16.7% and 84% of them were significant in this cohort of patients.
Brawley OW. Prostate cancer epidemiology
in the United States. World J Urol.
;30(2):195-200. Epub 2012/04/06.
Instituto Nacional de Cancerología. Información
sobre el cancer [internet]. Instituto
Nacional de Cancerologia; 2011 [updated
; cited 2014 ene 4]. Disponible en:
http://www.cancer.gov.co/contenido/contenido.
aspx?catID=434&conID=790.
Hodge KK, McNeal JE, Terris MK,
Stamey TA. Random systematic versus
directed ultrasound guided transrectal
core biopsies of the prostate. J Urol.
;142(1):71-4; discussion 4-5. Epub
/07/01.
Ukimura O, Coleman JA, de la Taille A,
Emberton M, Epstein JI, Freedland SJ, et
al. Contemporary role of systematic prostate
biopsies: indications, techniques, and
implications for patient care. Eur Urol.
;63(2):214-30. Epub 2012/10/02.
Naughton CK, Miller DC, Mager DE,
Ornstein DK, Catalona WJ. A prospective
randomized trial comparing 6 versus 12
prostate biopsy cores: impact on cancer
detection. J Urol. 2000;164(2):388-92.
Epub 2000/07/14.
Siu W, Dunn RL, Shah RB, Wei JT. Use
of extended pattern technique for initial
prostate biopsy. J Urol. 2005;174(2):505-
Epub 2005/07/12.
Scattoni V, Maccagnano C, Zanni G, Angiolilli
D, Raber M, Roscigno M, et al.
Is extended and saturation biopsy necessary?
Int J Urol.. 2010;17(5):432-47.
Epub 2010/04/27.
Maccagnano C, Gallina A, Roscigno M,
Raber M, Capitanio U, Sacca A, et al.
Prostate saturation biopsy following a first
negative biopsy: state of the art. Urol Int.
;89(2):126-35. Epub 2012/07/21.
Instituto Nacional de Cancerología, Sociedad
Colombiana de Urología. Guía
de práctica clínica (GPC) para la detección
temprana, diagnóstico, tratamiento
integral, seguimiento y rehabilitación de
pacientes con diagnóstico de cáncer de
próstata para el Sistema General de Seguridad
Social en Salud, Colombia [internet].
Bogotá: Ministerio de Salud y Protección
Social-Departamento Administrativo
de Ciencia Tecnología e Innovación
en Salud (Colciencias); 2013. Disponible
en: https://docs.supersalud.gov.co/
PortalWeb/Comunicaciones/GuiasPracticasClinica/
guia015-2013-cancer-deprostata-
-08-13.pdf
Centers for Disease Control and Prevention.
Cancer among men [internet];
[citado 2014 ene 4]. Disponible en:
http://www.cdc.gov/cancer/dcpc/data/
men.htm.
Carroll PR, Parsons JK, Andriole G,
Bahnson RR, Barocas DA, Catalona WJ,
et al. Prostate cancer early detection,
version 1.2014. Featured updates to the
NCCN Guidelines. J Natl Compr Canc
Netw. 2014;12(9):1211-9; quiz 9. Epub
/09/06.
Mottet N, Bastian P, Bellmunt J, van den
Bergh R, Bolla M, van Casteren N, et al.
Guidelines on prostate cancer. Eur Urol.
;65(1):124-37.
Greene KL, Albertsen PC, Babaian RJ,
Carter HB, Gann PH, Han M, et al. Prostate
specific antigen best practice statement:
update. J Urol. 2013;189(1
Suppl):S2-S11. Epub 2012/12/19.
Djavan B, Ravery V, Zlotta A, Dobronski
P, Dobrovits M, Fakhari M, et al. Prospective
evaluation of prostate cancer detected
on biopsies 1, 2, 3 and 4: when should
we stop? J Urol. 2001;166(5):1679-83.
Epub 2001/10/05.
Roehl KA, Antenor JA, Catalona WJ. Serial
biopsy results in prostate cancer screening
study. J Urol. 2002;167(6):2435-9.
Epub 2002/05/07.
Stewart CS, Leibovich BC, Weaver AL,
Lieber MM. Prostate cancer diagnosis
using a saturation needle biopsy technique
after previous negative sextant
biopsies. J Urol. 2001;166(1):86-91; discussion
-2. Epub 2001/07/04.
Epstein JI, Walsh PC, Carmichael M,
Brendler CB. Pathologic and clinical findings
to predict tumor extent of nonpalpable
(stage T1c) prostate cancer. JAMA.
;271(5):368-74. Epub 1994/02/02.
Zaytoun OM, Moussa AS, Gao T, Fareed
K, Jones JS. Office based transrectal saturation
biopsy improves prostate cancer
detection compared to extended biopsy
in the repeat biopsy population. J Urol.
;186(3):850-4. Epub 2011/07/27.
Bjurlin MA, Meng X, Le Nobin J, Wysock
JS, Lepor H, Rosenkrantz AB, et al. Optimization
of prostate biopsy: the role
of magnetic resonance imaging targeted
biopsy in detection, localization and risk
assessment. J Urol. 2014;192(3):648-58.
Epub 2014/04/29.
Hoeks CM, Schouten MG, Bomers JG,
Hoogendoorn SP, Hulsbergen-van de Kaa
CA, Hambrock T, et al. Three-Tesla magnetic
resonance-guided prostate biopsy in
men with increased prostate-specific antigen
and repeated, negative, random, systematic,
transrectal ultrasound biopsies:
detection of clinically significant prostate
cancers. Eur Urol. 2012;62(5):902-9.
Epub 2012/02/14.
Franiel T, Stephan C, Erbersdobler A,
Dietz E, Maxeiner A, Hell N, et al. Areas
suspicious for prostate cancer: MR-guided
biopsy in patients with at least one
transrectal US-guided biopsy with a negative
finding--multiparametric MR imaging
for detection and biopsy planning.
Radiology. 2011;259(1):162-72. Epub
/01/15.
Sciarra A, Panebianco V, Ciccariello M,
Salciccia S, Cattarino S, Lisi D, et al. Value
of magnetic resonance spectroscopy
imaging and dynamic contrast-enhanced
imaging for detecting prostate cancer foci
in men with prior negative biopsy. Clin
Cancer Res.. 2010;16(6):1875-83. Epub
/03/04.
Anastasiadis AG, Lichy MP, Nagele U,
Kuczyk MA, Merseburger AS, Hennenlotter
J, et al. MRI-guided biopsy of
the prostate increases diagnostic performance
in men with elevated or increasing
PSA levels after previous negative TRUS
biopsies. Eur Urol. 2006;50(4):738-48;
discussion 48-9. Epub 2006/04/25.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.